Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Recursion Pharmaceuticals Inc RXRX

Healthcare Biotechnology
Recursion Pharmaceuticals, Inc. is a clinical-stage TechBio company decoding biology to industrialize drug discovery. Its Recursion Operating System (OS), a platform built across diverse technologies, enables the Company to map and navigate trillions of biological and chemical relationships within the Recursion Data Universe. The Company integrates physical and digital components as iterative... see more

Recent & Breaking News (NDAQ:RXRX)

Recursion to Report Second Quarter 2024 Business Updates and Financial Results on August 8th

GlobeNewswire August 5, 2024

Recursion Announces Pricing of $200 Million Public Offering of Class A Common Stock

GlobeNewswire June 26, 2024

Recursion Announces Proposed Offering of Class A Common Stock

GlobeNewswire June 26, 2024

Recursion Gives Guidance on Seven Clinical Readouts within ~18 Months and Partnership Updates at Their Download Day

GlobeNewswire June 24, 2024

Recursion to Participate in Upcoming Investor Conferences

GlobeNewswire June 3, 2024

Power of Recursion OS on Display at Genome Scale in Nature Genetics Paper Detailing Potential Limitation of CRISPR Gene Editing Tool

GlobeNewswire May 29, 2024

Recursion Appoints Robert Hershberg M.D., Ph.D, as New Chair of the Board

GlobeNewswire May 24, 2024

Recursion Announces Completion of NVIDIA-Powered BioHive-2, the Largest Supercomputer in Pharmaceutical Industry

GlobeNewswire May 13, 2024

Recursion Provides Business Updates and Reports First Quarter 2024 Financial Results

GlobeNewswire May 9, 2024

Recursion to Report First Quarter 2024 Business Updates and Financial Results on May 9

GlobeNewswire May 2, 2024

Recursion to Participate in Upcoming Investor Conferences

GlobeNewswire May 1, 2024

Altitude Lab Secures Small Business Administration Growth Fund Accelerator Grant to Launch Horizon, a Commercialization Partnering Program

GlobeNewswire April 30, 2024

Recursion Appoints Najat Khan, PhD, as Chief R&D Officer and Chief Commercial Officer

GlobeNewswire April 16, 2024

Recursion to Participate in Upcoming Investor Conference

GlobeNewswire April 2, 2024

Recursion Publishes Annual Environmental, Social and Governance Report

GlobeNewswire March 26, 2024

Recursion Announces Plans to Open New Office in London

GlobeNewswire March 11, 2024

Recursion Hosts Second Annual Rare Disease Day Events for Utah's Rare Disease Community

GlobeNewswire March 1, 2024

Recursion to Participate in Upcoming Investor Conferences

GlobeNewswire March 1, 2024

Recursion Provides Business Updates and Reports Fourth Quarter and Fiscal Year 2023 Financial Results

GlobeNewswire February 27, 2024

Recursion to Host Public L(earnings) Call on February 27

GlobeNewswire February 20, 2024